Form 4: Novavax Executive Elaine O'Hara Reports Stock Transactions

Elaine O'Hara, EVP and Chief Strategy Officer of Novavax, reports the acquisition and disposal of common stock and restricted stock units on March 1, 2025.

Summary

• On March 1, 2025, Elaine O'Hara, the EVP, Chief Strategy Officer of Novavax, engaged in transactions involving Novavax common stock and restricted stock units (RSUs).
• O'Hara acquired 19,600 and 40,000 shares of common stock through the vesting of restricted stock units at a price of $0.
• She also disposed of 5,375 and 10,969 shares of common stock at a price of $8.33.
• Following these transactions, O'Hara directly owns 57,481 shares of Novavax common stock.
• She also owns 19,600 and 80,000 restricted stock units.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in the pharmaceutical industry. It provides transparency into the executive's holdings and transactions in the company's stock.

Comparison to Industry Standards

• Executive stock transactions are a common occurrence in publicly traded companies, including those in the biotechnology and pharmaceutical sectors.
• Similar filings are regularly made by executives at companies like Pfizer (PFE), Moderna (MRNA), and Johnson & Johnson (JNJ).
• The details disclosed, such as the number of shares, transaction prices, and ownership types, are standard across these filings.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly increasing the number of outstanding shares.
• The vesting of RSUs could be seen as a positive incentive for the executive.

Key Dates